首页> 外文期刊>Frontiers in Chemistry >Exploring the Interaction Mechanism Between Cyclopeptide DC3 and Androgen Receptor Using Molecular Dynamics Simulations and Free Energy Calculations
【24h】

Exploring the Interaction Mechanism Between Cyclopeptide DC3 and Androgen Receptor Using Molecular Dynamics Simulations and Free Energy Calculations

机译:利用分子动力学模拟和自由能计算探索环肽DC3与雄激素受体的相互作用机理

获取原文
           

摘要

Androgen receptor (AR) is a key target in the discovery of anti-PCa (Prostate Cancer) drugs. Recently, a novel cyclopeptide Diffusa Cyclotide-3 (DC3), isolated from Hedyotisdiffusa, has been experimentally demonstrated to inhibit the survival and growth of LNCap cells, which typically express T877A-mutated AR, the most frequently detected point mutation of AR in castration-resistant prostate cancer (CRPC). But the interaction mechanism between DC3 and AR is not clear. Here in this study we aim to explore the possible binding mode of DC3 to T877A-mutated AR from molecular perspective. Firstly, homology modeling was employed to construct the three-dimensional structure of the cyclopeptide DC3 using 2kux.1.A as the template. Then molecular docking, molecular dynamics (MD) simulations and molecular mechanics/generalized Born surface area (MM-GBSA) methods were performed to determine the bind site and explore the detailed interaction mechanism of DC3-AR complex. The obtained results suggested that the site formed by H11, loop888-893 and H12 (site 2) was the most possible position of DC3 binding to AR. Besides, hydrogen bonds, hydrophobic and electrostatic interactions play dominant roles in the recognition and combination of DC3-AR complex. The essential residues dominant in each interaction were specifically revealed. This work facilitates our understanding of the interaction mechanism of DC3 binding to AR at the molecular level and contributes to the rational cyclopeptide drug design for prostate cancer.
机译:雄激素受体(AR)是抗PCa(前列腺癌)药物发现的关键靶标。最近,通过实验证明,从猪痢疾七七中分离出的新型环肽Diffusa Cyclotide-3(DC3)可抑制LNCap细胞的存活和生长,该细胞通常表达T877A突变的AR,这是去势症中最常检测到的AR点突变。耐药性前列腺癌(CRPC)。但是DC3和AR之间的相互作用机制尚不清楚。在本研究中,我们旨在从分子角度探讨DC3与T877A突变型AR的可能结合方式。首先,以2kux.1.A为模板,通过同源性建模,构建了环肽DC3的三维结构。然后进行了分子对接,分子动力学(MD)模拟和分子力学/广义生化表面积(MM-GBSA)方法来确定结合位点,并探索了DC3-AR配合物的详细相互作用机理。获得的结果表明,由H11,loop888-893和H12形成的位点(位点2)是DC3与AR结合的最可能位置。此外,氢键,疏水和静电相互作用在DC3-AR配合物的识别和组合中起主要作用。明确揭示了每个相互作用中占优势的必需残基。这项工作有助于我们了解DC3与AR在分子水平上的相互作用机理,并有助于前列腺癌合理的环肽药物设计。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号